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Background: Ethiopia, a high tuberculosis (TB) burden country, reports one of the highest incidence rates of
extra-pulmonary TB dominated by cervical lymphadenitis (TBLN). Infection with Mycobacterium bovis has previously
been excluded as the main reason for the high rate of extrapulmonary TB in Ethiopia.
Methods: Here we examined demographic and clinical characteristics of 953 pulmonary (PTB) and 1198 TBLN
patients visiting 11 health facilities in distinct geographic areas of Ethiopia. Clinical characteristics were also
correlated with genotypes of the causative agent, Mycobacterium tuberculosis.
Results: No major patient or bacterial strain factor could be identified as being responsible for the high rate of
TBLN, and there was no association with HIV infection. However, analysis of the demographic data of involved
patients showed that having regular and direct contact with live animals was more associated with TBLN than with
PTB, although no M. bovis was isolated from patients with TBLN. Among PTB patients, those infected with Lineage
4 reported “contact with other TB patient” more often than patients infected with Lineage 3 did (OR = 1.6, CI 95%
1.0-2.7; p = 0.064). High fever, in contrast to low and moderate fever, was significantly associated with Lineage 4
(OR = 2.3; p = 0.024). On the other hand, TBLN cases infected with Lineage 4 tended to get milder symptoms overall
for the constitutional symptoms than those infected with Lineage 3.
Conclusions: The study suggests a complex role for multiple interacting factors in the epidemiology of
extrapulmonary TB in Ethiopia, including factors that can only be derived from population-based studies, which
may prove to be significant for TB control in Ethiopia.
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There were approximately 8.6 million new cases and 1.3
million deaths due to tuberculosis (TB) in 2012 [1].
Although pulmonary TB is the most common manifest-
ation, an estimated one million people (~15%) develop
extrapulmonary TB, of which TB lymphadenitis in the* Correspondence: aseffaa@gmail.com
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unless otherwise stated.cervical lymph nodes (TBLN) is the most frequent form
[2,3]. Failure to diagnose and treat TBLN can lead to ser-
ious health consequences such as disseminated TB [2].
The majority of all human TB cases are caused by
Mycobacterium tuberculosis but the closely-related
Mycobacterium bovis, the causative agent of TB in cattle
and a range of domestic and wild animals, can also cause
disease in humans. Zoonotic transmission can occur
through the aerosol route during close contact with
animals leading to pulmonary disease [4], but M. bovis isis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Berg et al. BMC Infectious Diseases  (2015) 15:112 Page 2 of 10primarily transmitted through consumption of contami-
nated milk and is often associated with TBLN [5].
Ethiopia, with a population of over 90 million people,
is among the countries with the highest TB burdens in
the world, with an incidence rate of 247 per 100,000 in
2012 [1]. Moreover, Ethiopia has reported a higher than
average incidence of extrapulmonary TB since records
started in the 1990s. What are the risk factors that can
explain this high rate of extrapulmonary TB in Ethiopia?
More than 80% of all extrapulmonary cases involve
cervical TB lymphadenitis that currently accounts for
around 33% of all incident TB cases in the country, with
a prevalence that roughly increases from 20% to 45% along
a south to north geographic axis (data from Ethiopian
Federal Ministry of Health; Figure 1). In parallel, Ethiopia
is home to the largest livestock population in Africa
with ~52 million cattle [6], and more than 80% of the
labour force works in the agricultural sector. As several
investigations have shown that bovine TB is endemic in
Ethiopian cattle [7,8] and reaches high prevalence in re-
gions with intensive husbandry systems [9-11], it would
seem plausible that zoonotic transmission of M. bovis
would have an influence on the prevalence of TBLN in
the country. However, in a large nation-wide molecular
epidemiology study [12] we explored the public health
risk for zoonotic TB in Ethiopia and concluded that the
overall role of M. bovis as a causative agent of TB in
humans was approximately only 1%. This led us toJinka
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Figure 1 Mapping of collection sites and extrapulmonary TB in Eth
(FMoH), Ethiopia.conclude that the high incidence rate of extrapulmonary
TB reported in Ethiopia is likely due to other factors.
In our molecular epidemiological study [12], nearly
1,000 mycobacterial strains were isolated from over 2,000
patients nationwide (Figure 1) who were diagnosed with
either TB lymphadenitis or pulmonary TB. In parallel to
identifying the pathogen population structure, demogra-
phic and clinical data were collected from the same pa-
tients. Here we report the results of our analyses of these
demographic and clinical data in an attempt to elucidate
the factors that influence rates of extrapulmonary TB in
Ethiopia and to inform public health control measures
generally.
Methods
Selection of study sites
The location of the study sites is shown in Figure 1 with
Gondar, Woldiya, Ghimbi, Fiche, and Butajira in the
Ethiopian highlands where subsistence farming domi-
nates, while Negelle, Filtu, and Jinka (“NFJ”; referred to
as one site in this paper) are located in the southern
parts of the country where people are mainly pastoralists
or agro-pastoralists. Fine needle aspirates (FNA) and
sputum samples, for diagnosis of TBLN and pulmonary
TB respectively, were collected from patients attend-
ing hospitals in Gondar, Woldiya, Ghimbi, Butajira and
Negelle. In addition, sputum samples were collected in
hospitals at Fiche, Jinka and Filtu, as well as health centresExtrapulmonary TB rates (%) 
reported by Ethiopian FMoH, 2008
Study site 
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iopia. Information received from the Federal Ministry of Health
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are mainly engaged in subsistence farming or in intensi-
fied dairy farming (Holeta, Sululta, and Chancho).
Collection of specimens and demographic and clinical
information
All consecutive and consenting patients with pulmonary
TB or TBLN presenting at hospitals or health centres
located in the study sites were recruited. Patients with
disseminated TB (e.g. evidence of combined lung and
lymph node disease) were excluded from the study.
Demographic and clinical information (including cardinal
symptoms and their duration: fever, night sweat, weight
loss, poor appetite, weakness, cough, and blood in sputum
as well as information on nodes such as number, size, and
consistency) was collected from each patient through an
interview with a clinician using the same questionnaire in
all health centres. Sputum samples were collected from
newly diagnosed pulmonary TB patients confirmed by the
health facility laboratory to have acid-fast bacilli (AFB) in
the sputum. The Ethiopian national algorithm (2008;
Additional file 1: Figure S1) was used for recruitment
of TB lymphadenitis patients, and patients diagnosed
with TBLN had an opportunity to be serologically tested
for HIV (no information on HIV status for pulmonary TB
cases was recorded in this study). FNA material was col-
lected aseptically from enlarged cervical lymph nodes with
a 21-gauge needle attached to a 10 ml syringe and smeared
onto glass slides for routine cytology. The remaining ma-
terial in the syringe was rinsed into a tube with 1 ml PBS
solution and used for culture. Sputum and FNA samples
were stored at 4°C at the field sites and during trans-
portation to the TB laboratory of the Armauer Hansen
Research Institute (AHRI) in Addis Ababa where they were
further processed within five days after sampling. For
remote collection sites (NFJ), samples were commonly
stored at the field site at −20°C until transport to AHRI.
Informed consent was obtained from all patients enrolled
in the study. All participating health facilities and regional
health bureaus provided support letters and ethical ap-
proval was obtained from the AHRI and the All Africa
Leprosy, Tuberculosis and Rehabilitation Training Centre
(ALERT) Ethics Review Committee, regional health
bureau ethics committees and the Ethiopian National
Research Ethical Review Committee.
Cytology and HIV testing
FNA smears were air dried on glass slides (at the collec-
tion site) and brought to AHRI for Ziehl-Neelsen and
Wright-staining (BDH chemicals Ltd, England). Cyto-
logical examination was performed by an experienced
pathologist for evidence of pathology indicative of tuber-
culosis and the results reported to the respective health
facilities for appropriate patient management. HIV testingwas done according to national guidelines at the health
facility where the patient was treated for TB and test pro-
cedures followed manufacturer’s instructions. Up to three
different tests were used: KHB rapid HIV; Stat-Pak HIV;
and Uni-gold HIV [13].
Culture and molecular typing
The procedures used for isolation and typing of the
causative agents from the recruited patients as well as
the molecular epidemiology outcomes have been pub-
lished elsewhere [7,12]. In brief, FNA and sputum sam-
ples collected from patients in this study were processed
and cultured at 37°C on three different media, including
two Löwenstein-Jensen (LJ) media (supplemented with
either glycerol or pyruvate) and a modified Middlebrook
7H11 medium optimised for the culture of M. bovis
[12,14]. Slants with no growth at week 8 were consid-
ered negative. Bacterial colonies from culture-positive
samples were Ziehl-Neelsen stained according to a stan-
dardized protocol to identify AFB. Cultures positive for
AFB were prepared as 20% glycerol stocks and stored
at −80°C. In parallel, heat-inactivated AFB positive
samples were investigated by multiplex PCR for Large
Sequence Polymorphism (LSP; e.g. RD4 and RD9) regions
and by lineage-specific single-nucleotide polymorphism
(SNP) analysis [7,15]. Isolates genetically typed as belong-
ing to the M. tuberculosis complex were spoligotyped as
previously described [16].
Statistical analysis
All data collected from patients and the laboratory were
double-entered into a Microsoft Access database and the
entry errors corrected with EpiInfo 3.5.1 (data compare
utility). Questionnaire and laboratory data were linked
by a unique identification code. Analyses of data were
done in STATA/IC 10 for Windows (StataCorp, College
Station, TX). Logistic regression models were used for
univariate analyses of crude odds ratios (OR) of demo-
graphic and clinical data and models were also adjusted
to age group (≤20 years, >20 to ≤45 years, >45 years),
sex and site (seven sites) to generate ORs adjusted to ex-
pected confounders ORs of demographic and potential
risk factors were further compared to those obtained in
the full model with all variables. We created binary out-
come variables for Lineages 3, 4 and 7 (the respective
lineage vs. all other lineages) to test associations with ex-
planatory variables such as pulmonary TB and TBLN. The
statistical significance threshold was set at 0.05, p ≤ 0.05.
Results
Study population and Sample collected
During a period of five years from 2006–2010, we
screened 2151 patients with untreated clinically diag-
nosed pulmonary TB and TB lymphadenitis (TBLN) in
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tients attending clinics in Gondar and Woldiya were
predominantly Amhara, while the majority of people in
Ghimbi, Fiche and the suburban clinics of Addis Ababa
were Oromo. The population in Butajira was mainly
Gurage, and clinics in the south (Negelle/Filtu/Jinka)
included people of Oromo, Somali, Amhara, and Ari
ethnic groups.
Clinics at Fiche and Addis Ababa did not use fine nee-
dle aspirates (FNA) for diagnosis of TBLN and therefore
only sputum from pulmonary TB cases was collected
from these sites. The yield of AFB positive cultures
differed between sites, likely reflecting logistic issues
associated with sample transport (Table 1).
Bacterial culture and clinical features
Acid-fast bacilli were isolated from 1212 of the 2151
patients (Table 1). As expected, AFB positive cultures
were obtained more frequently from the 953 patients
with smear-positive pulmonary disease than from the
1198 patients with suspected TBLN, with an average
yield between the collection sites of 79% and 38%
culture positivity, respectively. In comparison, Ziehl-
Neelsen staining of 302 FNA samples demonstrated
only 10% smear-positivity, reflecting challenges in diagno-
sis of TBLN by different methods. However, the frequency
of positive TBLN cultures was higher in FNA samples that
showed cytological evidence of tuberculosis (220 positive
cultures from 469 samples; 47%) than those with negative
cytology (23 positive cultures from 131 samples; 18%).
Our analysis of clinical features of patients diagnosed
with TBLN and pulmonary TB with regard to culture
outcome can be found in Additional file 2: Table S2 and
Additional file 3: Table S3A. Constitutional symptoms
(i.e. fever, night sweat, weight loss, poor appetite, and
weakness) were more frequent in patients where a positive
culture could be confirmed, reaching statistical signi-
ficance for “night sweat” and “weakness” for patients ofTable 1 Patient numbers enrolled and AFB culture-positivity
per collection site
Collection
site
Pulmonary TB TB lymphadenitis
Patients Culture-positive Patients Culture-positive
Gondar 120 103 (86%) 156 46 (29%)
Woldiya 36 30 (83%) 333 160 (48%)
Ghimbi 68 65 (96%) 264 99 (38%)
Fiche 223 203 (91%) 0 -
Addis Ababa 122 76 (62%) 0 -
Butajira 101 99 (98%) 360 138 (38%)
Negelle/
Filtu/Jinka
283 180 (64%) 85 13 (15%)
Total 953 756 (79%) 1198 456 (38%)both disease outcomes compared to those negative on cul-
ture. For patients diagnosed with TBLN, significant differ-
ences were also noticed in culture positivity related to
perceived increased rate and duration of neck swelling;
culture positivity was higher in “fast” swelling as compared
to “slow” swelling of the cervical lymph nodes (38% versus
54%) (Additional file 3: Table S3), and with regard to the
duration, TBLN patients seeking health care within one
month of the appearance of swelling were significantly
more likely to be culture-positive than those who were ex-
amined only one year after appearance. Culture-positivity
also tended to increase in proportion to node size; 103/
288 (36%) of samples from lymph nodes less than 1 cm
yielded positive cultures, in comparison to 58/137 (42%)
of samples from lymph nodes greater than 4 cm [adjusted
OR (95% CI) 2.3 (0.9-5.8)]. The median duration of swell-
ing recorded for all recruited TBLN patients was 12 weeks
and the average size of swollen lymph nodes was approxi-
mately 3 cm. For additional results on clinical features, see
Additional file 2: Table S2 and Additional file 3: Table S3.
Patients diagnosed with TBLN at the clinics had an
opportunity to be serologically tested for HIV. We ob-
tained 395 records for HIV status, of which 14 (3.6%)
were HIV positive. Five of these 14 HIV positive patients
were confirmed with TBLN by positive mycobacterial
culture. No HIV data were collected from pulmonary
TB patients.
Demographic information
In an attempt to elucidate risk factors associated with
disease type, we then compared 626 patients with pul-
monary TB and 328 with TBLN for their demographic
characteristics (Table 2). Having regular and direct con-
tact with live animals, was a significant risk factor for
TBLN when compared to pulmonary TB. In addition, an
association was observed between education and TBLN,
with patients having a degree from secondary school or
higher education being at lower risk of developing TBLN
in comparison to pulmonary TB (Table 2). We also ana-
lysed our data within each study site to investigate if
there was any association between ethnic group and dis-
ease outcome. This could not be analysed on a national
level as sites and ethnic groups were highly correlated
and affected by sampling bias. No associations between
ethnic groups and TBLN or pulmonary TB were found
(data not shown).
The role of M. tuberculosis lineages in clinical presentation
The M. tuberculosis complex strains that caused TB
in the 954 patients have been previously reported by
Firdessa et al. [12]. A summary of the lineage distribution
of these strains is shown in Figure 2, stratified by TBLN
and pulmonary TB cases, respectively. Here we have made
use of this information to seek correlations between
Table 2 Demographic characteristic of 954 culture-positive patients with identified strain
PTB TBLN Crude OR Adjusted OR
n % n % 95% CI 95% CI
Agea ≤20 years 128 51.6 120 48.4 1 1
>20 - ≤45 years 355 70.6 148 29.4 0.4 (0.3-06.)*** 0.5 (0.4-0.8)**
>45 years 87 80.6 21 19.4 0.3 (0.2-0.4)*** 0.3 (0.2-0.6)***
Sexb Male 331 70.6 138 29.4
Female 246 59.6 167 40.4 1.6 (1.2-2.2)*** 1.6 (1.1-2.3)*
Education Illiterate 311 67.2 152 32.8 1 1
Primary 158 58.5 112 41.5 1.5 (1.1-2.0)* 0.7 (0.4-1.1)
Secondary 86 71.7 34 28.3 0.8 (0.5-1.3) 0.3 (0.2-0.6)***
Higher degree 22 81.5 5 18.5 0.5 (0.2-1.3) 0.2 (0.1-0.7)**
Previous TB contact No 331 59.8 223 40.2
Yes 154 66.7 77 33.3 0.7 (0.5-1.0) 0.8 (0.5-1.3)
Intake of raw milk No 221 66.4 112 33.6
Yes 353 64.6 193 35.4 1.1 (0.8-1.4) 1.9 (1.2-2.8)**
Living with animals in
same household
No 289 70.2 123 29.8
Yes 273 60.7 177 39.3 1.5 (1.1-2.0)** 1.7 (1.1-2.6)*
Regular and direct contact
with live animals
No 214 72.0 83 28.0
Yes 327 64.9 177 35.1 1.4 (1.0-1.9)* 3.0 (1.9-4.5)***
BCG vaccination No 329 82.5 70 17.5
Yes 89 77.4 26 22.6 1.4 (0.8-2.3) 1.6 (0.8-3.3)
aadjusted for sex and site alone; badjusted for age and site alone; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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losis. Demographic and clinical data from the 328 patients
with TBLN and the 626 cases with pulmonary TB were
therefore stratified by M. tuberculosis lineage. Due to low
statistical power for lineages with limited isolates, only
Lineage 3 and Lineage 4 were compared individually
to all other lineages (Additional file 2: Table S2A and
Additional file 3: Table S3A). Analysis of demographic
factors among pulmonary TB patients showed a border-
line statistical difference between TB contact and M.1.6
24.2
70.9
2.7 0.6 0.3
23.9
70.0
5.8 0.0
L1 L3 L4 L7 Mb L1 L3 L4 L7 Mb
PTB                               TBLN
Figure 2 Representative lineages (in percentage) of M.
tuberculosis complex strains collected from TB lymphadenitis
and pulmonary TB patients in Ethiopia (data taken from
Firdessa et al. [10]). Mb, M. bovis) PTB = pulmonary TB,
TBLN = tuberculous lymphadenitis.tuberculosis lineage causing the disease; patients infected
with Lineage 4 reported “contact with other TB patient”
more often than patients infected with Lineage 3 did
(OR = 1.6, CI 95% 1.0-2.7; p = 0.064). The analogous
comparison in TBLN patients showed no significant dif-
ference. Moreover, pulmonary TB patients infected with
Lineage 4 strains – in contrast to Lineage 3 – tended to
have a more severe manifestation (OR > 1) for a majority
of the constitutional symptoms (Additional file 2: Table
S2A and Additional file 3: Table S3A). Fever was the most
distinct symptom in this regard and it was further en-
hanced when data on type of fever was included (data not
shown); high fever, in contrast to low and moderate fever,
was significantly associated with Lineage 4 (OR = 2.3;
p = 0.024). Corresponding data collected from the TBLN
patients generated a similar but reverse result: TBLN
cases infected with Lineage 4 tended to get milder symp-
toms overall for the constitutional symptoms than those
infected with Lineage 3.
Discussion
This study identified no major patient or bacterial strain
factor that alone could be responsible for the high rate
of TBLN in Ethiopia. In addition, no association was
found with HIV infection.
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vast majority is TBLN, among TB patients in Ethiopia
has steadily increased since the 1990s, reaching an aver-
age of around 33% across the country. Iwnetu et al. [17]
questioned if this increase was simply due to over-
diagnosis, with their study concluding that up to 15% of
all TBLN cases could be wrongly diagnosed; however,
this clearly does not completely explain the high inci-
dence of extrapulmonary TB. We recently tested the hy-
pothesis that TBLN in Ethiopia would be associated
with zoonotic transmission of M. bovis from cattle [12].
Molecular identification of the causative agents showed
that the contribution of M. bovis to human TB was less
than 1%. Even more unexpected was the fact that no TB
lymphadenitis patient was diagnosed with M. bovis in-
fection, but instead, the four human cases identified with
M. bovis infection all had pulmonary TB. This suggests
that other risk factors need to be considered to explain
the high incidence of extrapulmonary TB in Ethiopia
[18,19]. To search for additional risk factors, our exten-
sive health centre-based survey was also designed to
overlap geographically with areas previously examined
for bovine TB in cattle [7,10,20,21] and to include sites
distributed across the documented south–north gradient
(20-45%) of extrapulmonary TB (Figure 1). Based on fur-
ther analysis of our epidemiological study presented here
and elsewhere [7,12], we suggest a set of possible factors
that may influence the high incidence of extrapulmonary
TB as well as the lower than expected burden of M.
bovis infections in humans.
Zoonotic TB – M. bovis
The low incidence of human infection by M. bovis may
simply reflect a relatively low prevalence of bovine TB.
In the 1930s and 40s, it was estimated that 30-40% of
cattle in England and Wales had TB, with zoonotic
transmission suggested to account for around 5-6% of
the human TB burden [22,23]. In comparison, preva-
lence rates of 1-10% for bovine TB in Ethiopian zebu
cattle grazing in pasture are relatively low [7,21] and
may therefore have a lower impact on the overall contri-
bution to human TB in Ethiopia.
The low rate of isolation of M. bovis in humans re-
corded by us [12] can be compared to other reports that
used genotyping of isolates for definitive characterisa-
tion. Recent studies identified 3.5% of human TB in
Madagascar as caused by M. bovis [24], but found no M.
bovis in Côte d’Ivoire [25], in Brazil [26], or in Chad [27]
despite the fact that these countries are endemic for
bovine TB in cattle [28-32]. Higher rates were found in
Mexico, with separate studies identifying 6% and 28% of
human mycobacterial isolates as M. bovis [33,34]. Taken
together, these findings suggest a low overall rate of zoo-
notic transmission of M. bovis, particularly in Africa, butdo not exclude this as a public health concern in selec-
ted areas. Of particular note in the context of the
present study is that we did not sample TBLN cases in
urban areas where there are high rates of bovine TB
associated with intensified dairy farming [9,11,35]. At a
global level, systematic surveys in additional geographic
regions will be important in making a realistic assessment
of the human health risk posed by zoonotic transmission
of M. bovis. The high frequency of M. bovis isolated from
Mexican patients may be linked to the low overall TB
incidence rate (17/100,000), and it can be anticipated that
the relative contribution of zoonotic transmission will
increase as control programmes for humans progress to-
wards TB elimination, particularly when programmes
against bovine TB in cattle are lagging behind [36].
Accurate speciation of the causative agent in individuals
with TB is not trivial and demands time and resources.
Although newly developed PCR-based techniques can
identify specific mycobacteria directly from infected hu-
man specimens [37], isolation of the bacteria by culturing -
prior to further characterisation – is considered as the
diagnostic gold standard due to significantly higher sensi-
tivity and specificity. We do not think that our low rates
of M. bovis isolation from humans were simply due to
sample processing techniques that selected against M.
bovis; we routinely cultured M. bovis from cattle samples
from the same sites using the same protocols. The trad-
itional method to distinguish between species within the
M. tuberculosis complex has primarily been biochemical
testing based on phenotypic differences such as nitrate
reduction [38] and pyrazinamide resistance [39]. However,
the reliability of phenotype-based assays to accurately
distinguish between M. tuberculosis and M. bovis has been
contested [40,41]. Therefore, reservations regarding con-
clusions of earlier studies based solely on biochemical
tests or cultural characteristics are justified. The currently
well-established genotyping methods (e.g. LSP and SNP
typing), as used in this study, should be a requirement for
definitive differentiation of species from the M. tubercu-
losis complex.
Zoonotic TB – M. tuberculosis
From our initial hypothesis that the high prevalence of
extrapulmonary TB may reflect zoonotic transmission,
we anticipated that TBLN patients might have close
contact with farm animals and/or consume raw milk.
This was in fact the case. Our demographic analysis
identified contact with livestock as a risk factor for
TBLN when compared to pulmonary TB. Given the
large cattle population in Ethiopia (~50 million) and that
humans and cattle live in close proximity, together with
reports that M. tuberculosis has been isolated both from
cattle [7,42,43] and milk samples [44], there would
appear to be ample opportunity for direct involvement
Table 3 Representation of M. tuberculosis Lineage 4
among TB lymphadenitis and pulmonary TB cases from
respective collection sites
PTB TBLN Crude OR
N % n %
Gondar 60 84.5 11 15.5
32 60.4 21 39.6 3.6 (1.5-8.3)** 0.003
Woldiya 14 20.0 56 80.0
9 14.3 54 85.7 1.5 (0.6-3.8) 0.4
Ghimbi 7 38.9 11 61.1
40 40.8 58 59.2 0.9 (0.3-2.6) 0.9
Butajira 10 34.5 19 65.5
60 39.7 91 60.3 0.8 (0.3-1.8) 0.6
Negelle/Filtu/Jinka 38 95.0 2 5.0
123 96.1 5 3.9 0.8 (0.1-4.1) 0.8
**p ≤ 0.01 PTB = pulmonary tuberculosis; TBLN = tuberculous lymphadenitis;
OR = odds ratio.
Adjusted OR; adjusted for site (n = 7), age category (3) and sex (binary).
L3 = Lineage 3 (CAS); L4 = Lineage 4 (Euro-American); L7 = Lineage 7 (new).
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In our study of bovine TB in Ethiopia based on visual
inspection of carcasses and culture of suspect lesions,
we obtained 8 M. tuberculosis isolates from 32,800 ani-
mals [7], corresponding to a “culture-proven” prevalence
of 24 cases per 100,000. In comparison, the prevalence
of smear-positive TB in humans is 74 cases per 100,000
in Ethiopia [1]. In addition, the comparative intradermal
skin test that is used to assess bovine TB prevalence may
overestimate true prevalence of M. bovis infection as the
test cannot distinguish between cattle infected with M.
bovis or M. tuberculosis. In fact, a recent Ethiopian study
isolated both M. bovis and M. tuberculosis at similar
rates from skin-test reactor cattle in small-holder farms
owned by households with a TB index case [43]. Taken
together, even if the extent of cattle infected with M.
tuberculosis is unknown it should be considered as a
potential risk factor for human transmission, with for
example ingestion of contaminated milk being one pos-
sible source of infection. The contribution of zoonotic
transmission of M. tuberculosis to the high rate of extra-
pulmonary TB remains to be clarified. As epidemio-
logical data from Ethiopia suggest a higher prevalence of
M. bovis in cattle as compared to M. tuberculosis, one
would expect that the rate of zoonotic transmission of
M. bovis would be higher than that for M. tuberculosis.
However, several unanswered questions remain to be
solved in this human-cattle-human transmission cycle,
including transmission routes and rates as well as dif-
ferences in pathogenicity between M. bovis and M.
tuberculosis in cattle and humans.
Lineage and disease presentation
Having ruled out M. bovis as a cause for the high inci-
dence of TBLN, we can ask whether particular features
of the circulating M. tuberculosis strains might play a
role. An association of strains belonging to M. tuberculosis
Lineage 4 with pulmonary TB as opposed to extra-
pulmonary disease in the form of TB meningitis has been
described in Vietnam [45]. Similarly, Lari et al. [46] have
shown an association between Lineage 3 and extra-
pulmonary TB. Across Ethiopia as a whole, we did not ob-
serve any association between M. tuberculosis lineage and
disease presentation (Figure 2). Increased representation
of Lineage 4 in contrast to Lineage 3 in TBLN (data not
shown) was however observed in the north of the country
but it only reached statistical significance in Gondar
(Table 3). Lineage differences were also identified by
comparison of disease severity indicators; infection
with Lineage 4 was weakly associated with increased
severity in pulmonary TB patients, and with decreased se-
verity in TBLN. While these results are consistent with
the hypothesis that genetic diversity of M. tuberculosis
is associated with phenotypic diversity linked to diseasepresentation [47-49], these differences do not provide
an obvious explanation for the high overall rate, or for
the North–south gradient, of extrapulmonary TB in
Ethiopia.
There is evidence of distinct geographic structuring of
M. tuberculosis populations in Ethiopia. Representation
of Lineage 3 was up to four times higher in the north as
compared to the other sites. A recent study in neigh-
bouring Sudan also reported a high frequency of Lineage
3, with SIT 25 (the predominant Lineage 3 spoligotype
in Ethiopia) accounting for almost half of the M. tuber-
culosis isolates [50]. In contrast, Lineage 1, which has
been reported at high frequency in Somalia (~50% (129/
256); SITVIT2), was isolated only from sites in southern
Ethiopia. In comparison to Ethiopia, Sudan (25%) and
Somalia (20%) reported lower case notifications of extra-
pulmonary TB in 2012 [1]. Based on these reports from
Sudan and current data from Ethiopia, we cannot propose
a correlation between a high rate of extrapulmonary TB
and infection with Lineage 3 (subtype SIT 25) strains; this
is also shown by our observation that Lineage 4 (rather
than Lineage 3) is associated with TBLN in Gondar.
Similarly, the two major subtypes of Lineage 4 (Spoligo-
types SIT 149 and SIT 53) were relatively well distributed
among the collection sites in Ethiopia and no strong
clustering towards the north (e.g. Gondar) was observed.
Thus, no obvious relationship between subtype and disease
manifestation was found, but such a correlation cannot be
excluded. We conclude that while M. tuberculosis genotype
may have some effect on disease presentation, it cannot
account for the overall elevation in the prevalence of extra-
pulmonary TB in Ethiopia.
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Co-infection with HIV is strongly associated with in-
creased rates of extrapulmonary TB [51-53]. While the
rate of HIV-TB co-infected patients in Ethiopia (10.2%
of all incident cases) is higher than in neighbouring
Sudan and Somalia (7.5% and 3.6% respectively), it is
much lower than that in Kenya (39%), which has an inci-
dent rate of extrapulmonary TB (18%) approximately
half of that reported for Ethiopia [1]. Working within
national control programme guidelines in our present
study, we obtained HIV infection data for 399 patients
with TBLN; the rate of HIV-positivity (3.6%) was below
the national average reported for all TB cases. Though
limited number of patients were compared, we conclude
that HIV co-infection does not explain the high rate of
extrapulmonary TB, confirming observations of several
previous studies in Ethiopia [17,54].
Data from the Ethiopian FMoH (2008) and analysed
by us (data not shown) suggests that the total incidence
of both TB and TBLN are positively associated with the
proportion of urban population in Ethiopian regions.
This likely reflects an urban population with easier ac-
cess to health services and TB diagnostics than people
living in more rural regions, and thus, may also influ-
ence the proportion of TBLN cases among all TB cases.
Specifically, seeking health care may be particularly low
for people with TBLN among rural populations with
long distances from a health centre, as has been sug-
gested for pastoralists living in the Afar region [55,56].
The Ethiopian human population is characterised by a
high level of genetic diversity [57,58] and, although not
studied here, host genetics may well have an influence
on disease presentation [59]. In general, the incidence of
extrapulmonary TB in North African countries is higher
than that in Sub-Saharan Africa [1]. Assuming a human
genetic effect, the high rates in Ethiopia may reflect the
known admixture of northern and southern African hu-
man ancestry, and/or perhaps particular host and patho-
gen genotype combinations. Future analyses of disease
outcomes as a function of different host-pathogen com-
binations may provide insights into the pathogenesis of
TB and complement conventional genome-wide associ-
ation studies [60,61].
A limitation of this study is that it is based on clinical
cases visiting health facilities that enrolled smear positive
pulmonary and cervical lymphadenitis TB cases. There
was no prospective follow up to determine clinical out-
come. Smear negative pulmonary and non-cervical
extrapulmonary TB cases have not been included. Pul-
monary TB cases were not tested for HIV. An epidemio-
logical investigation with active case detection would
have avoided the possible bias due to differential health
seeking-behaviour and access to care. Nevertheless, our
study provides very valuable insight into the epidemiologyof TB in Ethiopia and will inform control in this and other
high burden TB countries.
Conclusions
Why Ethiopia stands out as a country with a high burden
of extrapulmonary TB is enigmatic. Zoonotic transmission
of M. bovis infection has been excluded as a major factor
in TBLN, as was infection with HIV. Instead, the answer
is likely to be more complex, and here we have presented
several factors that could play significant roles, including
zoonotic transmission of M. tuberculosis and genetic fea-
tures of the pathogen and/or the host population. The
study suggests a complex role for multiple interacting
factors in the epidemiology of extrapulmonary TB in
Ethiopia, including factors that can only be derived from
population-based studies, which may prove to be signifi-
cant for TB control in Ethiopia. We conclude that elucida-
tion of the epidemiology of TBLN will contribute to a
better understanding of the factors that maintain TB as a
whole, rather than just pulmonary TB alone, and hence to
improved disease control.
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